drugset / Trial / NCT06167681
The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease
NaSequentialOpen-labelTreatment
Summary
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's disease.
Timeline
- Start
- 2024-01-17
- Primary completion
- 2025-12
- Completion
- 2029-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NouvNeu001 | Cell therapy | — | Other |